Every day, we respond to difficult situations that can happen to any of us.
Our experienced Employees provide effective assistance to those in urgent need. Always.
We love our work. We are united by the belief that every human life and health is precious. That's why we help all people when they are in need. We protect health and life. This is more than just a job. It is a service.
According to the World Health Organization (WHO), migraine is one of the 20 most negatively affecting human life and the second highest health burden after strokes. Sometimes its symptoms exclude the patient from normal functioning for days. It is recurrent in nature, consisting of symptoms that herald a migraine attack, headaches along with accompanying gastrointestinal and neurological symptoms. Migraine is more common in women than in men. The frequency of its appearance also varies by age group. People between the ages of 25 and 55 are most likely to suffer from it, which is when we are most active. Migraine, according to experts, affects between 2.75 million and 6.5 million people in our country (including probable migraine). 230,000 to 550,000 suffer from chronic migraine, the most severe form.
The patient experiences migraine pain unilaterally, pulsating, of high intensity. It is intensified by physical activity, even as insignificant as head movement. It is also accompanied by other symptoms. Often the patient suffers from nausea, vomiting, which makes it difficult to take medication. The pain can last up to 72 hours. Chronic migraine sufferers experience pain for at least 15 days a month. That's why it's so important to have effective therapy, which has been available to few. - After many years of joint efforts, not only by the Polish Headache Society, but also by the Polish Neurological Society, the first drug program for the most severely ill patients, those with chronic migraine, has been finalized, says PTBG President Dr. Magdalena Boczarska-Jedynak.
The program will reimburse two monoclonal antibodies and botulinum toxin, which have previously been used in the treatment of chronic migraine, but for many patients its high purchase cost has been an insurmountable barrier. The therapy will be available only in a drug program, which will be conducted at selected centers in Poland. There are 30 to 40 such sites planned throughout Poland.
Antidepressants, antiepileptics and antihypertensive drugs are often used to treat migraine. These drugs have not always been effective or well tolerated by patients. Causal therapies that affect the mechanism of migraine formation have been lacking. Erenumab is the first migraine prevention therapy approved by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). It is an anti-CGRP monoclonal antibody that blocks the CGRP receptor (CGRP-R), a protein that plays a key role in the pathomechanism of migraine. The use of several doses of erenumab allows for a rapid improvement and reduction in the frequency and intensity of migraine attacks.
